Technical Analysis for EYEG - AB Corporate Bond ETF

Grade Last Price % Change Price Change
D 35.36 0.10% 0.04
EYEG closed up 0.1 percent on Monday, March 18, 2024, on 1 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Narrow Range Bar Range Contraction 0.10%
Overbought Stochastic Strength 0.10%
Down 3 Days in a Row Weakness 0.10%
Down 4 Days in a Row Weakness 0.10%
Gapped Down Weakness 0.10%
Narrow Range Bar Range Contraction -0.48%
Overbought Stochastic Strength -0.48%
Down 3 Days in a Row Weakness -0.48%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AB Corporate Bond ETF Description

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.


Classification

Keywords: Pharmaceutical Disease Stem Cell Eye Diseases Macular Edema Diabetic Macular Edema Uveitis Allergic Conjunctivitis Dry Eye Disease Hyaluronic Acid Conjunctivitis Lineage Cell Therapeutics Viral Conjunctivitis Medical Signs Non Infectious Posterior Uveitis

Is EYEG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.7828
52 Week Low 34.9178
Average Volume 222
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 35.28
10-Day Moving Average 35.46
Average True Range 0.10
RSI (14) 51.46
ADX 9.97
+DI 49.96
-DI 47.85
Chandelier Exit (Long, 3 ATRs) 35.33
Chandelier Exit (Short, 3 ATRs) 35.23
Upper Bollinger Bands 35.71
Lower Bollinger Band 34.85
Percent B (%b) 0.59
BandWidth 2.43
MACD Line 0.03
MACD Signal Line 0.00
MACD Histogram 0.0246
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.36
Resistance 3 (R3) 35.36 35.36 35.36
Resistance 2 (R2) 35.36 35.36 35.36 35.36
Resistance 1 (R1) 35.36 35.36 35.36 35.36 35.36
Pivot Point 35.36 35.36 35.36 35.36 35.36
Support 1 (S1) 35.36 35.36 35.36 35.36 35.36
Support 2 (S2) 35.36 35.36 35.36 35.36
Support 3 (S3) 35.36 35.36 35.36
Support 4 (S4) 35.36